Sameeh M Salama is the Vice President (VP) of Business Development at Fedora Pharmaceuticals, VP of Business Development at the management and business consultancy firm, Brass Dome Ventures, and was formerly VP of NAEJA Pharmaceuticals.
Since his move to industry in 1994, he has been heavily involved in antibacterial and antifungal research. His most recent research involved the initial discovery of a series of potent β-lactamase inhibitors which were later licensed to Roche and are now in clinical development.
Sameeh has been with Fedora since its inception in 2011. At NAEJA, he was actively involved in over a dozen licensing and partnership agreements, including the licensing of NAEJA’s Beta-lactamase inhibitors to Fedora, and later the licensing of the same assets to F. Hoffman-La Roche in a record-setting US$750 million license deal.
Sameeh was also involved in securing contract research agreements, strategic planning and establishing a wide network of contacts within the industry worldwide. Before joining NAEJA, he was Director of Microbiology at SynPhar Laboratories.
Sameeh has published over 50 original research articles and presentations given at international congresses. He has six original patents in the areas of anti-infective and anti-inflammatory disease.
Sameeh received his PhD in medical microbiology in 1990 from the University of Salford, UK, and spent four years as a post-doctoral fellow with Dr Diane E Taylor at the University of Alberta in Edmonton, Canada.